ArticleTranslational oncology2026
ARID1A regulates colorectal cancer metastasis through the AKT/mTOR/p70S6K pathway.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is the most common malignant tumor of the digestive system. Exploring effective diagnostic markers and therapeutic targets has great significance for the diagnosis and treatment of CRC. ARID1A is frequently mutated in CRC, but its prognostic value for this disease remains controversial. Therefore, our aim was to explore the biological role of ARID1A in CRC and the underlying molecular mechanisms.
methodsThe clinical relevance of ARID1A in CRC was evaluated using integrating multiple biological databases and a clinical cohort. In vitro and in vivo functional assays (CCK-8, colony formation, transwell, and xenograft models) assessed its tumor-modulating effects. Autophagy was examined via transmission electron microscopy and immunofluorescence, while western blotting quantified epithelial-mesenchymal transition, autophagy-related, and signaling pathway proteins.
resultsBased on CRC mutation data from TCGA-COAD and cBioPortal, the ARID1A mutation frequency was 14% and 16%, respectively. Survival analysis showed that the low-ARID1A-expression group had a poorer prognosis than the high-expression group. In vitro and in vivo studies showed that downregulation of ARID1A promotes various malignant biological behaviors of CRC cells, including proliferation, invasion, and metastasis. These phenotypic changes were accompanied by alterations in autophagy-related markers (such as decreased Beclin1 and LC3B, and increased p62) and activation of the AKT/mTOR/p70S6K signaling pathway. In addition, analyses of clinical samples indicated that low ARID1A expression is an independent risk factor for CRC recurrence and metastasis.
conclusionIn summary, ARID1A has a tumor-suppressive role in CRC. These data suggest that ARID1A expression is a potential biomarker for CRC, which could lead to novel clinical diagnostic and treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.